7 days ago
Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Guggenheim analyst Vamil Divan reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $65.00. The company's shares opened today at $21.27.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Divan covers the Healthcare sector, focusing on stocks such as Insmed, Johnson & Johnson, and Pfizer. According to TipRanks, Divan has an average return of 4.6% and a 51.02% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vera Therapeutics with a $67.36 average price target, implying a 216.76% upside from current levels. In a report released today, TD Cowen also reiterated a Buy rating on the stock with a $60.00 price target.
